Zmiany w składzie tkankowym obserwowane w trakcie terapii ciężkich zaburzeń funkcji tarczycy

Stangierski, Adam; Ruchała, Marek; Krauze, Tomasz; Moczko, Jerzy; Guzik, Przemysław

doi:10.5603/ep.a2016.0025

Cited by 12 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these circumstances the body composition responses to T 4 treatment may not be the same as seen in our study. A reduction in FM on treatment of hypothyroidism was also observed by Stangierski et al [16]. However, they used a whole body bioimpedance analyzer for body composition analysis, whereas we used DEXA, which is generally considered to be more accurate.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Correction of Hypothyroidism Leads to Change in Lean Body Mass without Altering Insulin Resistance

et al. 2016

View full text Add to dashboard Cite

Background: Hypothyroidism is associated with insulin resistance, dyslipidemia, and abnormal body composition. This study assessed changes in body composition and insulin resistance after thyroxine (T₄) replacement in overt hypothyroidism. Methods: In this prospective longitudinal study carried out in a tertiary care center, adult nondiabetic patients with overt hypothyroidism were rendered euthyroid on T₄. Anthropometry including skinfold thickness (SFT) at the triceps and subscapularis was recorded. Patients underwent testing for fasting plasma glucose, creatinine, serum insulin, T₄, thyrotropin (TSH) and body composition analysis by dual-energy X-ray absorptiometry (DEXA) both before and at 2 months after restoration to the euthyroid state. Results: Twenty-seven patients (20 female and 7 male) aged 35.3 ± 11.0 years (min-max: 17-59 years) with overt hypothyroidism were recruited. Serum T₄ at the time of recruitment was 48.9 ± 24.6 nmol/l (normal range = 64.4-142 nmol/l). All patients had TSH ≥50 µIU/l. Following treatment, there was a mean body weight reduction of 1.7 kg (p = 0.01). Waist circumference as well as triceps and subscapularis SFT decreased significantly (p < 0.001). There was no change in fat mass (FM), percentage of fat (%FM) or bone mineral content in any of the specified regions or in the body as a whole. In contrast, mean lean body mass (LBM) decreased significantly by 0.8 kg (p < 0.01) in the trunk and 1.3 kg (p < 0.01) in the whole body. Insulin resistance and level of glycemia were not affected by treatment with T₄. Conclusion: LBM decreases significantly without affecting FM after correction of hypothyroidism. Insulin resistance was not influenced by T₄ treatment.

show abstract

Section: Discussionmentioning

confidence: 91%

“…In another study by Cerit et al [15], the mean body weight fell by 1.2 kg in 28 hypothyroid patients after thyroid hormone replacement. Stangierski et al [16] observed a reduction in median body mass from 72.35 to 69.3 kg following the treatment of hypothyroidism (p < 0.0005).…”

Section: Discussionmentioning

confidence: 99%

Correction of Hypothyroidism Leads to Change in Lean Body Mass without Altering Insulin Resistance

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It is known that hormone treatment restores muscle mass and promotes an improvement in functionality. Thus, the diagnosis and early control of the disease becomes important [64,65].…”

Section: Discussionmentioning

confidence: 99%

What are the factors associated with sarcopenia-related variables in adult women with severe obesity?

et al. 2020

View full text Add to dashboard Cite

Background: Understanding the association between sarcopenia-related variables and several risk factors may help to implement interventions aimed at preventing its occurrence by reducing or controlling the identified risk factors. Although changes in body composition occur in both sexes, in women, muscle loss is accentuated due to decreased estrogen levels following menopause. This study aims to determine the factors associated with sarcopenia-related parameters in middle-aged women identified with class II/III obesity (body mass index [BMI] ≥ 35 kg/m 2). Methods: The study included 104 women with severe obesity (40.23 ± 8.49 years) with an average body fat percentage of 52.45 ± 4.14%. Sarcopenia was assessed using total appendicular skeletal muscle mass (ASMM), appendicular skeletal muscle mass index (ASMMI), and appendicular skeletal muscle mass adjusted by BMI (ASMM/BMI) as evaluated using dual energy X-ray absorptiometry (DXA). Hand grip strength (HGS) and HGS adjusted by BMI (HGS/BMI) were evaluated using dynamometry. Functional performance was assessed using the walking speed test (WS). The explanatory variables were age, lifestyle, comorbidities, food consumption, and metabolic parameters. A multivariate linear regression was performed. Results: Factors associated with sarcopenia-related variables in 104 severely obese women with a mean BMI of 43.85 kg/ m 2 were as follows: ASMMI negatively correlated with serum levels of tetraiodothyronine (T4) and tobacco use; ASMM/ BMI negatively correlated with age, serum T4 levels, and diabetes; ASMM negatively correlated with T4 serum levels and diabetes; HGS negatively correlated with age and hypercholesterolemia, and positively correlated with low-density lipoprotein cholesterol (LDL-c); HGS/BMI negatively correlated with age and hypercholesterolemia and positively correlated with LDL-c; and WS negatively correlated with hypothyroidism and diabetes. Conclusion: In severely obese women, muscle mass and function were inversely associated with age, smoking status, endocrine parameters, hypercholesterolemia, and comorbidities such as diabetes. Thus, the results of this investigation are relevant in supporting the development of clinical interventions to aid in the prevention of sarcopenia in adult women with severe obesity.

show abstract

“…One has to keep in mind that, contrary to the everyday practice, one is not dealing with a previously healthy patient in whom the symptoms appear instantly. Here the first symptoms such as fatigue, weakness, loss of appetite, and change in body mass can be attributed to the underlying cancer [28,29]. Hence one should actively seek the symptoms of hormonal dysfunction, especially taking precise history during each cycle and ordering additional biochemical tests when needed.…”

Section: The Endocrine Adverse Reactionsmentioning

confidence: 99%

“…Należy pamiętać, iż w odróżnieniu od sytuacji, z którymi w swojej codziennej praktyce spotyka się endokrynolog, nie mamy do czynienia z pacjentem dotychczas zdrowym, u którego objawy pojawiają się nagle. Pierwsze symptomy dysfunkcji hormonalnej pod postacią zmęczenia, osłabienia, braku apetytu, zmiany masy ciała mogą więc zostać powiązane z chorobą nowotworową trwającą od dłuższego czasu [28,29]. Objawów zaburzeń hormonalnych należy więc poszukiwać aktywnie, przede wszystkim przeprowadzać dokładny wywiad z chorym podczas każdego kolejnego podania leku i zlecać badania biochemiczne w razie wskazań.…”

Section: Streszczenieunclassified

Endocrine complications of cancer immunotherapy

Król

Gawlik

Jarząb

2018

Endokrynologia Polska

View full text Add to dashboard Cite

Immunotherapy using monoclonal antibodies -checkpoint inhibitors -is a dynamically evolving discipline of clinical oncology and a new hope for patients with advanced and disseminated cancer. However, the activation of T-lymphocytes can at the same time lead to autoimmune response and destruction of healthy organs, which is a serious adverse effect that can also affect the endocrine system. Here we present possible endocrine complications of immunotherapy with contemporary inhibitors of immune checkpoints (CTLA-4, PD-1, PD-L1/L2), their frequency, symptoms, and proposed grade-dependent treatment. Failure to diagnose endocrine pathology can in adverse circumstances lead to treatment failure and condemn the patient's fate. Due to tremendous progress in cancer immunotherapy during the last few years and an increase in the number of treated patients, endocrinologists should become acquainted with the specificity of this mode of oncological treatment. (Endokrynol Pol 2018; 69 (6): 722-733)  Endocrine complications of immunotherapy Aleksandra Król et al.

show abstract

Zmiany w składzie tkankowym obserwowane w trakcie terapii ciężkich zaburzeń funkcji tarczycy

Cited by 12 publications

References 35 publications

Correction of Hypothyroidism Leads to Change in Lean Body Mass without Altering Insulin Resistance

Correction of Hypothyroidism Leads to Change in Lean Body Mass without Altering Insulin Resistance

What are the factors associated with sarcopenia-related variables in adult women with severe obesity?

Endocrine complications of cancer immunotherapy

Contact Info

Product

Resources

About